Commercial Pfizer protects $6.4bn heart disease blockbuster from generics, for now Pharmaceutical TechnologyPfizer's Vyndamax will be free from generics competition until 2031 in a boost to the company's revenue streams.CardiovascularRead full story pharminent April 29, 2026 (Last updated: April 30, 2026) Pharmaceutical Technology Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams. Cardiovascular Read full story Post navigation Previous: Chiesi to buy KalVista in $1.9B deal for rare disease drugNext: Avalyn, in pursuit of better lung drugs, banks $300M in an IPO Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026